Clinical Trials · NCT02207348
Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 24
- Start date
- Aug 2014
- Locations
- 1 site, Germany
- Primary endpoint
- Area under the liraglutide plasma concentration time curve from 0 to last quantifiable observation (tz) after single dose